Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tiotropium bromide
- Development stage
- Approved
- Lead developer
- Arven İlaç
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Tutast is a brand of tiotropium bromide developed by Arven Pharmaceuticals. It is a long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Tiotropium works by blocking muscarinic M3 receptors in the bronchial smooth muscle, leading to sustained bronchodilation and improvement in lung function. It is delivered via inhalation using the Sanohaler dry powder inhaler device.
- Brand names
- TutastTutast Sanohaler
- Other names
- tiotropium bromide
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)CHRM5 (M5)CHRM2 (M2)CHRM4 (M4)
Beyond the preview
Go deeper on tiotropium bromide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tiotropium bromide.